신경 보호 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Neuroprotection Market size is expected to reach USD 85.72 Billion in 2034 from USD 43.46 Billion (2025) growing at a CAGR of 7.84% during 2026-2034.

The Global Neuroprotection Market is gaining traction due to rising prevalence of neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and stroke-related complications. Increasing research investments in neuroscience and growing clinical trials for innovative neuroprotective agents are driving market expansion. Pharmaceutical companies are focusing on therapies that prevent neuronal damage and improve long-term cognitive outcomes.

Growth drivers include the aging global population, heightened awareness about early diagnosis, and advancements in biomarker-based detection techniques. Government funding for neurological research and supportive regulatory frameworks are encouraging drug development. Additionally, partnerships between biotech firms and academic institutions are accelerating innovation in neuroprotective therapies.

In the coming years, personalized medicine and gene-based therapies are expected to transform the neuroprotection landscape. Emerging treatment modalities, including stem cell therapy and neurotrophic factors, will likely create new revenue streams. Expanding healthcare infrastructure in emerging economies and improved patient access to advanced therapies will further strengthen long-term market prospects.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Type

• Free Radical Trapping Agents (Antioxidants)
• Glutamate Antagonists (Anti-excitotoxic Agents)
• Apoptosis Inhibitors
• Anti-inflammatory Agents
• Neurotrophic Factors (NTFs)
• Metal Ion Chelators
• Stimulants
• Others

By Application

• Prevention
• Treatment

COMPANIES PROFILED

• Daiichi Sankyo Company, , Eli Lilly and Company, AbbVie Inc, Dr Reddys Laboratories Ltd, Teva Pharmaceutical Industries Ltd, Novartis AG, AstraZeneca plc, Astrocyte Pharmaceuticals Inc, F HoffmannLa Roche AG, Biogen Inc, Pfizer Inc, Johnson Johnson, Merck Co Inc, Gilead Sciences, Amgen Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL NEUROPROTECTION MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Type
• 4.2. Free Radical Trapping Agents (Antioxidants) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Glutamate Antagonists (Anti-excitotoxic Agents) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Apoptosis Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Anti-inflammatory Agents Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Neurotrophic Factors (NTFs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Metal Ion Chelators Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Stimulants Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.9. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL NEUROPROTECTION MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Prevention Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Treatment Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL NEUROPROTECTION MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Drug Type
  • 6.2.2 By Application
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Drug Type
  • 6.3.2 By Application
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Drug Type
  • 6.4.2 By Application
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Drug Type
  • 6.5.2 By Application
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Drug Type
  • 6.6.2 By Application
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL NEUROPROTECTION INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Eli Lilly And Company
  • 8.2.2 AbbVie Inc
  • 8.2.3 Dr. Reddy'S Laboratories Ltd
  • 8.2.4 Teva Pharmaceutical Industries Ltd
  • 8.2.5 Novartis AG
  • 8.2.6 AstraZeneca Plc
  • 8.2.7 Astrocyte Pharmaceuticals Inc
  • 8.2.8 F. Hoffmann-La Roche AG
  • 8.2.9 Biogen Inc
  • 8.2.10 Pfizer Inc
  • 8.2.11 Johnson & Johnson
  • 8.2.12 Merck & Co. Inc
  • 8.2.13 Gilead Sciences
  • 8.2.14 Amgen Inc